Related Experiment Videos
Cardiac disease in chronic uremia: investigation
1Department of Nephrology/Hypertension, Cleveland Clinic Foundation, OH 44195, USA.
Insights
Cardiovascular disease is the primary cause of death in end-stage renal disease (ESRD) patients. This review details clinical screening tools for detecting cardiovascular disease in ESRD patients, aiding nephrologists and cardiologists.
Area of Science:
- Nephrology
- Cardiology
- Internal Medicine
Background:
- Cardiovascular disease (CVD) is the leading cause of mortality in end-stage renal disease (ESRD) patients.
- Nearly half of deaths in the dialysis population are attributed to CVD.
- Early detection of CVD is critical for improving outcomes in ESRD patients.
Purpose of the Study:
- To review available clinical screening tools for detecting symptomatic and asymptomatic cardiovascular disease in ESRD patients.
- To provide an overview of left ventricular (LV) function assessment in hemodialysis patients.
- To outline noninvasive cardiovascular screening strategies for patients awaiting renal transplantation.
Main Methods:
- Review of clinical screening tools for cardiovascular disease in ESRD.
- Detailed overview of left ventricular (LV) function assessment in hemodialysis.
- Guidelines for pre-transplantation cardiac evaluation based on risk factors, symptoms, and stress testing (thallium or dobutamine echocardiography).
Main Results:
- Guidelines for pre-transplantation cardiac evaluation are provided.
- Current studies on hemodialysis populations may not be generalizable to all ESRD patients.
- Further research is needed to clarify the utility of cardiovascular screening and intervention in the broader ESRD population.
Conclusions:
- Effective screening tools are essential for managing cardiovascular disease in ESRD.
- Pre-transplantation cardiac evaluation requires a tailored approach based on individual patient profiles.
- The optimal role and utility of cardiovascular screening and intervention in the general ESRD population require further investigation.
Abstract:
Cardiovascular disease continues to be the leading cause of death in the end-stage renal disease (ESRD) population, accounting for nearly half of the deaths among the dialysis population. The purpose of this article is to review the clinical screening tools available to the attending nephrologist and consulting cardiologist to detect both symptomatic and asymptomatic cardiovascular disease in ESRD patients. The author presents a detailed overview of (1) assessment of left ventricular (LV) function in the hemodialysis population and (2) noninvasive cardiovascular screening in patients before anticipated renal transplantation. Specific guidelines are offered for the pretransplantation evaluation of cardiac disease based on the patient's cardiovascular risk factors, symptomatology, and stress testing with either thallium or dobutamine echocardiography. Recent studies of cardiovascular screening in selected hemodialysis populations may not be extrapolated to the general ESRD population pending further investigation. Crucial questions relating to the utility of cardiovascular screening and intervention in the general ESRD population remain and deserve further study.